SHENZHEN, China, May 13, 2024
/PRNewswire/ -- On May 10, 2024,
the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory
(BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking a significant advance in the
province's efforts to address public health challenges. Utilizing
the '13311i GigaLab' technological framework, this facility
supports vital life and health science research, enhancing the
region's capacity to produce innovative health solutions.
The '13311i' framework is at the forefront of proactive health
management, integrating whole genome sequencing with analyses
of blood, urine, and fecal samples and sophisticated
imaging techniques such as CT, ultrasound, and MRI. With
detailed health and disease risk profiles, it sets the stage for
breakthroughs in early detection and personalized
treatment, critical tenets of precision
medicine.
The opening ceremony featured BGI Group CEO and BGI Genomics
Vice Chairman Yin Ye, BGI Genomics
Vice President Li Zhiping, and BGI Genomics Northeast Region
General Manager Su Hang, along with
Heilongjiang Longwei Precision Medicine Laboratory Chairman Jia
Lipeng.
Colorectal cancer, a focal point of the Lab's research, is
ranked as the third most common cancer worldwide and the second
leading cause of cancer-related deaths. According to the "Global
Cancer Statistics 2020" report by the World Health Organization,
there were over 1.9 million new cases of CRC and nearly 930,000
deaths in 2020. The Lab's initiatives address this significant
health burden with the world's highest throughput sequencer,
DNBSEQ-T20×2, enhancing the efficiency and quality of
diagnostics.
The laboratory's first significant initiative involves assessing
colorectal cancer risks for nearly 800,000 eligible for screening
(45-64-year-old residents), employing gene methylation technology
for early detection and preventive care. This large-scale public
health effort exemplifies the Lab's commitment to precision
medicine, tailored to combat public health issues more
effectively.
Yin Ye remarked, "By integrating
our latest technologies, we are poised to make
significant contributions to global public health, particularly in
managing chronic diseases and shaping future medical
practices."
The BGI-HL OHA Intelligent Laboratory also spearheads the
'13311i' project to develop a comprehensive technical system for
disease prevention and health management across the entire
population and lifecycle. This project utilizes a genomics-based
approach and integrates various data forms, from high-resolution
imaging to real-time physiological data collected through wearable
devices, ensuring a holistic view of health risks and outcomes.
Looking ahead, this Lab plans to broaden its impact through
extensive genomic research projects that will benefit public
health, precision medicine, and even modern agriculture. This
facility is committed to advancing Heilongjiang's digital and biotech ecosystem
and contributing to public health improvements by
applying the latest life science technologies.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bgi-hl-oha-lab-inaugurated-in-harbin-initiating-colorectal-cancer-risk-assessment-for-800-000--302143251.html
SOURCE BGI Genomics Co., Ltd.